Looking ahead, Wall Street forecasts adjusted EPS of $23.21 for fiscal 2025, representing a 78.7% increase from $12.99 in ...

So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss. “If you can buy it ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ablation, according to a large Veterans Affairs database. New initiators ...

SAN DIEGO, CA—Glucagon-like peptide-1 (GLP-1) receptor agonists may be useful for secondary prevention of atrial fibrillation (AF) in patients with obesity and type 2 diabetes, new results from the ...

You can reach Elaine on Signal at elaineywchen.70. The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options.

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...

After attracting criticism for admitting that she uses a GLP-1 medication to help lose weight, Janelle Rohner claimed she refunded fans who purchased her health programs. In a TikTok video shared ...

Nearly all of the world's top pharmaceutical companies are racing to develop new oral GLP-1 drugs, including: Amgen®, AstraZenca, Eli Lilly, Merck®, Novo Nordisk®, Pfizer®, and Roche®.

The rise of GLP-1 weight loss drugs represents a shift in the way consumers approach their health goals The rise of GLP-1 drugs for weight loss represents a remarkable shift in the way people ...

Expanding Medicare coverage for GLP-1RAs could significantly increase spending, despite potential savings from reduced obesity-related comorbidities. A microsimulation model projected a net ...